Filing Flows › Ensysce Biosciences (ENSC) › Q3 2025
Ensysce Biosciences (ENSC) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 14, 2025
Ensysce Biosciences (ENSC) reported revenue of $493K for the third quarter 2025 (Q3 2025), -86% from a year earlier and -64% from the quarter before. Operating margin was -758.7%, net loss $3.7M (756.3% of revenue).
Ensysce Biosciences, Q3 2025: revenue $493K (-86% year over year), operating margin -758.7%, net loss $3.7M, operating cash flow −$1.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $493K | -64% | -86% |
| Operating profit | −$3.7M | — | — |
| Net earnings | −$3.7M | — | — |
| Operating cash flow | −$1.9M | — | — |
What changed
Revenue was $493K in Q3 2025, down 86% year over year and down 64% from the previous quarter.
Operating costs exceeded revenue by $3.7M, an operating margin of -758.7%. Total costs grew 53% against a revenue fall of 86%. The fastest-growing cost line was Research & development (+75%). The quarter ended with a net loss of $3.7M, wider than the previous quarter's $1.7M loss.
Operating cash flow was −$1.9M. Non-cash charges added back $46K of share-based compensation. Working capital and other items added $1.8M.
Questions
What was Ensysce Biosciences' revenue in the third quarter 2025?
Ensysce Biosciences (ENSC) reported revenue of $493K for the third quarter 2025 (Q3 2025), -86% from a year earlier and -64% from the quarter before.
Was Ensysce Biosciences profitable in the third quarter 2025?
Operating loss was $3.7M (-758.7% of revenue) and net loss $3.7M.